Thanks.
It is worth noting the below as this is quite important for likelihood of success of dosing and readouts for the AML trials. Simplistically the historic data is like a crystal ball for the results to come.
In AML, Bisantrene achieved complete responses rates 40% to 72% range (average 52%) as a single-agent in 5 out 5 historic Phase II trials (1987 to 1994) .
Even with effectively half the number of cycles ( no consolidation course given ), the Israel trial that finished in 2020 achieved a 40% response rate ( effectively with half the drug given ). This was the reduction in tumour size in that 2020 trial.
The above result mid 2020 plus the release of the Cancer Cell paper about 10 days later drove a 269% rerate in the share price over a 1 month period.
Thanks. It is worth noting the below as this is quite important...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.095(7.22%) |
Mkt cap ! $234.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.41 | $1.32 | $249.8K | 182.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2826 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 40000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.37 |
Change
0.095 ( 6.64 %) |
||||
| Open | High | Low | Volume | ||
| $1.34 | $1.41 | $1.32 | 16145 | ||
| Last updated 15.53pm 10/05/2024 ? | |||||
| RAC (ASX) Chart |